FDA Grants Orphan Drug Designation to IKT-001 for PAH
IKT sits 67% above its 52-week low of $1.33.
Summary
The FDA granted Orphan Drug Designation to IKT-001 for pulmonary arterial hypertension, a milestone that brings tax credits, fee exemptions, and seven years of market exclusivity upon approval. This follows the recent $50M ATM sale to RA Capital and the ongoing pivotal Phase 3 IMPROVE-PAH trial. The designation validates the unmet need in a ~50,000-patient U.S. market and strengthens the regulatory pathway for a drug that could be the first once-daily oral antiproliferative for PAH. With a market cap near $287M and a cash runway extended by the recent financing, the ODD adds a tangible, non-dilutive value driver. Enrollment progress in the Phase 3 trial remains the key operational catalyst.
At the time of this announcement, IKT was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $286.5M. The 52-week trading range was $1.33 to $2.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.